58 results about "Type ii diabetes" patented technology

The application discloses application of Xintong preparation in preparation of a medicine for treating diabetes and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The Xintong preparation is prepared from 13 raw medicinal materials of Huangqi, Gegen, Danshen, Dangshen, Maidong, Heshouwu, Yinyanghuo, Dangui, Zaokesheng, Haizao, Kelp, Muli and Zhishi, has the effects of benefiting qi and activating blood, reducing phlegm and dredging collaterals. Pharmacodynamic experiments show that the Xintong preparation has the effect of reducing blood sugar, can effectively improve the physical conditions of polydipsia, polyphagia, polyuria and emaciation and lack of strength of an animal model of diabetes, significantly reduces the fasting blood sugar and serum insulin level, improves the oral glucose tolerance, has a definite treatment effect on type II diabetes, and expands the clinical application range of the Xintong preparation, and has a wide market application prospect.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The invention belongs to the technical field of food additives, and particularly discloses dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid and a preparation method and application thereof.The dictyophora rubrovolvata beta-glucan in dictyophora rubrovolvata is extracted through a water extraction and alcohol precipitation method, and the extract has good physiological activities such as blood sugar lowering activity and immunity. And compounding the dictyophora rubrovolvata beta-glucan and erythritol through a series of steps of sol dissolving, decocting and cooling, so as to prepare the dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid. The prepared dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid is applied to preparation of low-calorie soft sweets, the situation that traditional soft sweets with gelatin as a gelling agent are low in nutritional value and rich in saccharides, and the risk of chronic diseases such as obesity, decayed teeth, hyperglycemia and type II diabetes mellitus can be possibly increased is broken through, and the prepared dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid has the advantages of being simple in preparation process, low in cost and the like. And a development direction is provided for researching and developing a novel functional gelling agent into soft sweets.

The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.

A method for detecting and treating Type II Diabetes includes the use of hsa_piR_020485, a PIWI-interacting RNA isolated from urinary extracellular vesicles (ECVs), as a biomarker for the diagnosis and treatment of Type 2 diabetes mellitus (T2DM). The method is non-invasive, utilizing the differential expression of hsa_piR_020485 in diabetic versus non-diabetic subjects to identify subjects in need of treatment for T2DM. The method includes obtaining a urine sample from a subject, isolating urinary ECVs from the urine sample, extracting total RNA from the isolated urinary ECVs, quantifying hsa_piR_020485 levels from the total RNA, determining if the hsa_piR_020485 expression level exceeds a threshold, and administering one or more T2DM treatments.

The invention discloses a stem cell medicine for pancreas islet repair and application, and belongs to the technical field of stem cell biology, and the stem cell medicine for pancreas islet repair is prepared by compounding a carrier, pancreatic progenitor cells and pancreas islet-like cells in proportion. The problems that in the prior art, due to the fact that stem cells are unstable in differentiation efficiency, poor in synergistic effect and poor in biocompatibility, islet injury cannot be repaired, and diabetes cannot be treated are solved. According to the present invention, the dual mechanisms of endogenous beta cell repair and exogenous beta cell supplement are adopted, and the beta cell function recovery and the group structure reconstruction are synchronously achieved through the reasonable ratio, such that the in-vivo blood glucose of the mouse is significantly reduced, the beta cell number and the glucose tolerance dose of the mouse are increased, and the low immunogenicity and the high anti-inflammatory property are simultaneously provided. The compound can be used for treating type I and type II diabetes mellitus, improving the insulin secretion function and relieving local inflammatory response of pancreas by promoting pancreas islet beta cell proliferation, and has application potential in treatment of type I and type II diabetes mellitus and pancreas islet repair.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The present disclosure relates to a pharmaceutical formulation suitable for sublingual administration for use in the treatment of obesity, type II diabetes, or related diseases. The pharmaceutical formula comprises 5 to 10 milligrams of glucagon-like peptide-1 receptor agonist peptide (GLP-1 RA-P) which is dissolved in 1.5 to 2.0 milliliters of a buffer solution, and the pH (Potential of Hydrogen) value of the pharmaceutical formula is 5.5 to 7.5. The disclosure also discloses a method for treating obesity, type II diabetes, or related diseases. The method comprises administering the pharmaceutical formulation of the present disclosure to a subject in a sublingual administration, and allowing the pharmaceutical formulation to be continuously located sublingually of the subject for 5-10 minutes, where the pharmaceutical formulation has a bioavailability for GLP-1 RA-P of 2-10% compared to the administration to the subject through subcutaneous injection.

Provided are GIPR and GLP-1R co-agonistic polypeptides, or pharmaceutically acceptable salts, amides or esters thereof, and uses of the polypeptides, salts, amides or esters, including treatment of type II diabetes, obesity, overweight, and the like.

The invention relates to the field of biological medicine, and discloses a protein degradation targeting chimera (PROTAC) compound targeting 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) and medical application of the protein degradation targeting chimera (PROTAC) compound. The compound comprises a structural unit shown as a formula I, X is a 11 beta-HSD1 binding ligand, Y is a connecting chain, Z is an E3 ubiquitin ligase ligand, ubiquitination degradation of 11 beta-HSD1 can be induced, and therefore the function of the compound can be regulated and controlled at the protein level. Different from a traditional small-molecule inhibitor, the degradation agent can significantly reduce expression of 11 beta-HSD1 in cells and improve glucocorticoid signal abnormality, and shows a novel action mode at molecular and cellular levels. In diabetes, obesity, lipid metabolism disorder and related complication models, the compound can reduce blood sugar, improve insulin sensitivity, regulate blood fat and relieve inflammation, and shows a good treatment prospect. The half degradation concentration of a representative compound in vitro is about 1000 nM, and feasible degradation efficiency is achieved. The compound can be synthesized by Click chemistry and other methods, and can be prepared into a pharmaceutical composition for prevention and treatment of type II diabetes, metabolic syndrome, polycystic ovarian syndrome and other diseases, and a new strategy is provided for research and development of related drugs.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

A novel five-membered heteroaromatic imidazole compound and use thereof is disclosed herein. Specifically, disclosed is a compound as shown in formula (III) or a pharmaceutically acceptable salt thereof. Also disclosed is a method for treating a disease related to GLP-1 receptor such as type II diabetes.

A radiofrequency ablation system will comprise a radiofrequency ablation catheter. The radiofrequency ablation catheter will comprise an expandable ballon, an inner tube with a multi-lumen structure, a guidewire tube, an outer sheath, and a radiofrequency electrode. The radiofrequency electrode will be flexible with a metal electrode layer, liner layer, flexible conductor layer, and substrate layer. The radiofrequency ablation catheter can be used to treat a subject's condition by ablating target tissue, such as Type II Diabetes Mellitus. Diabetes can be treated or alleviated due to a decrease in a subject's blood glucose and weight in response to the ablation of the target tissue.

The present disclosure is directed to a bio-feedback sensor in combination with AI and ML that can be implemented to optimize neuromodulation parameters for the management of a medical condition such a type II diabetes. The bio-feedback obtained by the sensors is optimized by the ML tools to predict and recommend the upregulation or downregulating the neuroregulators to modulate treatment. The algorithms could also learn to sense a life-threating pathological state, or bio-chemical imbalance, and in the case of diabetes a life-threating low blood sugar level the system overrides to stimulate the target fibers that control organs to regulate blood glucose levels.

The present disclosure provides compounds of the formula:and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.

In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.

Disclosed are peptides that are useful as agonists of GPR56. Also disclosed are compositions comprising at least two synthetic or recombinant peptides, each of the peptides comprising a sequence selected from LLSSR, GYYCG, and NQGCKL, or a sequence that has a sequence identity of at least 60% thereto, wherein when a peptide comprises sequence a) or b) the peptide has a length of from 5-25 amino acids and wherein when a peptide comprises sequence c) the peptide has a length of from 6-26 amino acids. The compositions are useful for treating diseases or conditions such as vascular dysfunction, cardiovascular disease, impaired pancreatic -cell function, type II diabetes, impaired glucose tolerance, liver dysfunction, cirrhosis, liver cancer, depression, Alzheimer's disease, retinopathy and Attention deficit hyperactivity disorder.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition suitable for type II diabetes and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 to 45 parts of radix astragali seu hedysari, 20 to 30 parts of herba dendrobii, 30 to 45 parts of rhizoma polygonati, 20 to 30 parts of radix ophiopogonis and 20 to 30 parts of corn stigma. According to the traditional Chinese medicine composition, through the synergistic effect of core components such as astragalus membranaceus for tonifying qi, lifting yang, promoting salivation and nourishing blood, dendrobium nobile for tonifying stomach and promoting salivation, polygonatum kingianum for tonifying qi, nourishing yin, moistening lung and tonifying kidney, radix ophiopogonis for nourishing yin and promoting salivation and the like, glucose metabolism balance is effectively adjusted, insulin resistance is improved, and therefore the effect of reducing blood glucose and / or lipid is achieved.

The invention provides a GLP-1R / GIPR / GCGR triple receptor agonist and an application of the GLP-1R / GIPR / GCGR triple receptor Specifically, the invention provides a polypeptide with GLP-1 (glucagon-like peptide-1) R / GIPR / GCGR triple receptor agonist activity or a pharmaceutically acceptable salt thereof, and the polypeptide or the pharmaceutically acceptable salt thereof has obvious triple agonist activity of a glucagon-like peptide-1 (GLP-1) receptor, a gastric inhibitory polypeptide (GIP) receptor and a glucagon (GCG) receptor. The compound can be used for preparing pharmaceutical compositions for preventing or treating metabolic diseases such as type I diabetes mellitus, type II diabetes mellitus, gestational diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD), obesity, hyperlipidemia and the like.

The invention discloses a hyriopsis cumingii hypoglycemic polypeptide and application thereof. The amino acid sequence of the hyriopsis cumingii hypoglycemic polypeptide is as shown in SEQ ID NO.01. The IC50 value of the hyriopsis cumingii hypoglycemic polypeptide to alpha-glucosidase is 0.293 mmol / L, the IC50 value of the hyriopsis cumingii hypoglycemic polypeptide to dipeptidyl peptidase-IV is 34.78 mu mol / L, postprandial blood sugar rise can be effectively inhibited, insulin secretion is promoted, and the hyriopsis cumingii hypoglycemic polypeptide is suitable for adjuvant therapy and blood sugar management of type II diabetes patients.

Systems and methods for predicting a likelihood of a patient developing Type II diabetes are provided. Behavioral health data, mental health data, and / or neurological health data is obtained, risk factors from the health data are identified, and an at-risk score is calculated based on the one or more risk factors. The at-risk score is indicative of the likelihood of the patient developing Type II diabetes. The different types of health data can be weighed differently in calculating the at-risk score.

The present application relates to an exosome fusion liver-targeting liposome drug delivery system and its preparation method and application, and belongs to the field of polymer materials and pharmaceutical preparations. The present application discloses an exosome fusion liver-targeting liposome drug delivery system, which uses high-concentration PEG 8000 and Nycodenz in combination to synergistically improve the exosome and liposome fusion efficiency, form biomimetic vesicles with uniform size and high drug loading. The exosome not only can play the characteristics of anti-inflammatory and antioxidant, but also plays a role in resisting harsh gastrointestinal environment and crossing biological barriers. In addition, the liposome is modified by cholic acid derivative by using EDC / NHS mediated amidation reaction, which realizes precise targeting of liver and sufficient accumulation in liver. The above-mentioned effects synergistically realize the treatment of type II diabetes and non-alcoholic fatty liver disease.

The present invention relates to methods of reducing weight, HbA1c levels, high-sensitivity C-reactive protein, and systolic blood pressure in human patients comprising administering to the patient maridebart cafraglutide with the result being treatment of obesity, type II diabetes, and other obesity related conditions such as atherosclerotic cardiovascular disease and heart failure.

The application discloses a method for extracting Hericium erinaceus extract, and comprises the following steps: drying and crushing Hericium erinaceus to obtain Hericium erinaceus powder; putting the Hericium erinaceus powder into a carbon dioxide supercritical extraction kettle; and under the conditions of a pressure of 25-35 MP, a temperature of 30-40 DEG C, a time of 1-2 h and an ethanol content of 0-4 mL / g as a entraining agent, a Hericium erinaceus crude extract is obtained. The method is simple and environment-friendly, and the obtained monomer compound has the effect of preventing and treating type II diabetes.

The invention provides a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of hypoglycemic products, and relates to the technical field of traditional Chinese medicines. The invention discloses a traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials: 4-8 parts of ginseng stem and leaf saponin, 8-16 parts of astragalus polysaccharide, 6-12 parts of astragaloside, 8-16 parts of catalpol, 6-12 parts of rehmannia D, 8-16 parts of verbascoside, 3-5 parts of raspberry polysaccharide, 4-8 parts of ellagic acid, 4-8 parts of pachymaran, 5-10 parts of pachymic acid, 8-16 parts of lycium barbarum polysaccharide, 40-62 parts of schisandra chinensis, 20-40 parts of Chinese yam, 40-62 parts of radix ophiopogonis, 40-62 parts of radix trichosanthis and 40-62 parts of rhizoma alismatis. The traditional Chinese medicine raw materials are pretreated by using the high-voltage pulsed electric field, and then ethanol extraction treatment is performed twice, so that the yield of the traditional Chinese medicine extract is high, and the traditional Chinese medicine composition obtained by mixing the traditional Chinese medicine extract with other active ingredients has an excellent effect of treating type II diabetes mellitus.

The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.

The invention discloses a type II diabetes risk factor causal discovery method based on an improved graph auto-encoder. Performing preprocessing and Z-score standardization on the T2DM risk factor observation data; fusing the data generation model and the GAE, and constructing a nonlinear causal structure candidate space of the T2DM risk factors; introducing an acyclic constraint, an augmented Lagrange method and a bidirectional edge penalty term to establish a new scoring function, and optimizing function parameters through a gradient descent method to determine an optimized causal structure; and calculating the standardized inverse information entropy causal intensity of the optimized causal structure, designing a causal discovery algorithm flow, and outputting a final causal network structure. Aiming at the problems that T2DM risk factor coupling is serious, the sample size is small, and an existing nonlinear causal discovery method is difficult to meet acyclic hypothesis, so that a wrong causal relationship is caused, the potential nonlinear causal relationship can be effectively mined, the causal recognition accuracy is improved, and a new thought can be provided for diabetes prevention and treatment and research.

The invention relates to an engineered exosome drug delivery system with enhanced membrane fluidity as well as a preparation method and application of the engineered exosome drug delivery system. According to the system, unsaturated phospholipid is inserted into an exosome membrane, so that the membrane flowability of the exosome is enhanced on the premise of not damaging a natural structure and protein composition, and the entrapment efficiency of polypeptide proteins, nucleic acid and small-molecule chemical drugs is remarkably improved. The membrane fluidity is enhanced, the diffusivity, the cellular uptake efficiency and the transepithelial transport performance of the exosome in intestinal mucus are improved, and the physiological barrier of oral delivery can be effectively overcome. In type I and type II diabetes animal models, the system significantly improves the oral bioavailability of insulin and semaglutide, and shows an excellent blood sugar regulation effect. The preparation method is simple and convenient, the biocompatibility is good, and a novel delivery strategy with a good transformation prospect is provided for oral biological macromolecular and micromolecular chemical drugs.